BioMérieux: Sequential Acceleration Aided by US Tailwinds; Near-Term Outlook Cautious
BioMérieux's organic sales growth accelerated sequentially to 8% in the third quarter, driven by nonrespiratory panels, microbiology, and industrial applications. Management reconfirmed its full-year guidance, sending shares up by about 4% at market open on Nov. 3.